ArticleScientific reports2025
Astragalus polysaccharide alleviates diabetic nephropathy via SIRT1-dependent activation of FOXO3a/BNIP3 pathway to enhance podocyte autophagy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Astragalus polysaccharide (APS), a major bioactive component of Astragalus membranaceus, has received considerable attention for its potential in treating diabetes and its complications. However, whether its renoprotective effects in diabetic nephropathy (DN) involve autophagy modulation remains poorly understood. Here, Streptozotocin (STZ)-induced DN rats and high glucose (HG)-exposed mouse podocyte clone-5 (MPC5) cells were established as in vivo and in vitro models, respectively. APS effects were evaluated using renal function indicators, renal histopathology, and autophagy markers. Autophagic flux was assessed by MDC staining and transmission electron microscopy (TEM). Furthermore, SIRT1 silencing or overexpression in vitro was used to confirm its role in regulating autophagy and its interaction with the FOXO3a/BNIP3 pathway. APS treatment significantly reduced fasting blood glucose proteinuria, and glomerular hypertrophy in DN rats. Mechanistically, APS upregulated SIRT1 deacetylase activity, promoted FOXO3a nuclear translocation and activated BNIP3-mediated podocyte autophagy. In vitro, APS restored autophagic flux in MPC5 cells, evidenced by increased Beclin 1 expression, elevated LC3 II/LC3 I ratio and reduced p62 accumulation. MDC staining and TEM further confirmed enhanced autophagosome formation in podocytes following APS treatment. These findings demonstrate APS alleviates DN by enhancing podocyte autophagy via the SIRT1/FOXO3a/BNIP3 axis, thereby protecting renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.